In addition, B-cell maturation antigen (BCMA) and CS1 bispecific CAR-T cells exhibited superior activity to conventional CAR-T cell that only targeted BCMA in heterogeneous multiple myeloma [206]. Here, TNFRSF17 is linked to plasma cell myeloma.